Some preclinical and postmortem studies suggest that the effects of atypical antipsychotics could be mediated by brain-derived neurotrophic factor (BDNF). Olanzapine is an atypical antipsychotic with shown efficacy in psychosis treatment. The aim of this study was to compare plasma BDNF levels at baseline and after 1 year of olanzapine treatment in 18 drug-naive patients who experienced a first psychotic episode with those of 18 healthy control participants matched by age, sex, and socioeconomic level. Plasma BDNF levels were measured in patients at the index episode and at 1, 6, and 12 months of follow-up using an enzyme-linked immunosorbent assay. Symptoms and functioning of patients and controls were assessed with the Positive and Negative Symptom Scale and Global Assessment of Function Scale. BDNF levels of patients at onset were significantly lower than controls but increased toward control values during olanzapine treatment. There was a significant positive correlation between BDNF levels and functioning (Global Assessment of Function Scale). BDNF levels were also negatively correlated with positive symptoms, but not with negative symptoms or general psychopathology. Results suggest that olanzapine can offset the low BDNF levels at the onset of first psychotic episodes, and improving psychotic symptoms. The increase in BDNF levels may be its mechanism of action in improving positive symptoms. Int Clin Psychopharmacol 00:000-000 c 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins.
Introduction
Current theories suggest that dysfunctions in neural development and neural plasticity, such as decreased neural proliferation and migration, delayed myelination, and abnormal synaptic modeling, play a role in the pathophysiology of schizophrenia (Angelucci et al., 2005; Buckley et al., 2007a; Pillai, 2008) , and bipolar disorder (Duman, 2002) . Neurotrophic factors influence the development, maintenance, and function of the peripheral and central nervous systems. Brain-derived neurotrophic factor (BDNF), the most abundant neurotrophin in the brain, promotes the growth and maintenance of intercellular connections, modulates neurotransmission, and participates in plasticity mechanisms, like long-term potentiation and learning (Shoval and Weizman, 2005) . Consequently, abnormal BDNF signaling may influence neuronal differentiation and synaptic function, leading to altered brain development and functioning.
Several types of study have been used to investigate the possible role of BDNF in schizophrenia and bipolar disorder, but interpretation of the findings has been hampered by inconsistent or conflicting results. Postmortem studies have shown changes in the expression of the BDNF gene and its receptor TrkB in different brain areas of patients with schizophrenia (Pillai, 2008) . In a recent study of postmortem brain specimens, gene expression of BDNF was decreased in the dorsolateral prefrontal frontal cortex of patients diagnosed with schizophrenia or bipolar disorder compared with normal controls (Pillai, 2008) . However, other studies have reported an increase in BDNF concentrations in cortical areas (Durany et al., 2001 ). Animal models have been used to study the effect of antipsychotics on neurotrophic factors. Results from some of these studies have indicated that atypical antipsychotics enhance factors that promote cell survival, like BDNF, and may have differential effects from typical antipsychotics (like haloperidol), which reduce BDNF expression (Tohen et al., 2003; Thacker et al., 2006; Tan et al., 2007; Pillai, 2008) . In contrast, other rodent studies have found no effect of antipsychotics on BDNF expression or levels in brain tissue (Brown et al., 2008 , Valvassori et al., 2008 .
The ability of BDNF to cross the blood-brain barrier in humans (Pan et al., 1998) suggests that serum BDNF levels may reflect BDNF levels in the brain. Clinical studies have shown reduced serum BDNF levels in drugnaive first episode psychotic patients compared with healthy control participants (Palomino et al., 2006; Buckley et al., 2007b) . Moreover, serum BDNF levels correlated with positive symptoms (Buckley et al., 2007b) , and were increased after 6 months of treatment (atypical antipsychotics), but not after 4 weeks of treatment (Palomino et al., 2006) . Reduced serum BDNF levels have also been seen in patients with chronic schizophrenia (Toyooka et al., 2002; Grillo et al., 2007) , whereas other studies have failed to find any difference in serum BDNF levels between drug-naive patients with schizophrenia and control participants (Shimizu et al., 2003) .
Data on the effects of olanzapine treatment on plasma BDNF levels in patients diagnosed with psychosis is both limited and conflicting. Although some of the aforementioned preclinical and clinical studies showed a positive effect of olanzapine on restoring reduced BDNF levels (Thacker et al., 2006; Tan et al., 2007; Pillai, 2008; Rizos et al., 2008; Hammonds and Shim, 2009 ), similar effects were not seen in small samples of Japanese patients with schizophrenia (or first episode schizophrenia) after olanzapine treatment for 8 weeks (Hori et al., 2007; Yoshimura et al., 2008) . Nevertheless, an increase in plasma BDNF levels after olanzapine treatment was seen with longer periods of follow-up of about 6 months, at least in White patients diagnosed with a first psychotic episode (Palomino et al., 2006) . In addition, there was a marginal increase in BDNF levels in the dental gyrus of patients diagnosed with a first psychotic episode and treated with olanzapine for 4 weeks (Hammonds and Shim, 2009 ). Furthermore, serum BDNF levels increased in patients diagnosed with schizophrenia treated chronically with atypical antipsychotics (Gama et al., 2007) , and in 10 patients diagnosed with chronic schizophrenia and treated with olanzapine for 6 weeks (Rizos et al., 2008) . Some of the differences in results between studies could be because of differences in treatment duration and follow-up.
The aim of this study was to investigate the effect of olanzapine on plasma BDNF levels, symptoms and overall functioning in a sample of drug-naive first episode psychotic patients treated with olanzapine for 1 year, and to compare the findings with those in a healthy control group.
Materials and methods
The study included 18 patients (mean age ± S.E.M., 24.39 ± 6.53 years) from the health catchment area of Vitoria (Alava, Spain) who experienced a first psychotic episode during the period 2005-2007. First psychotic episode was defined as the first time a patient displayed positive psychotic symptoms of delusions or hallucinations (within a psychotic episode) of less than 6 months duration. Diagnoses were made at 12 months using the Structured Clinical Interview for Diagnostic and statistical manual of mental disorders, fourth edition, SCID-I. Of the 18 patients included in the study, 12 were diagnosed with schizophrenia, five with mania with psychotic symptoms, and the remaining one patient with psychotic disorder not otherwise specified. Only drug-naive patients were included in the study, although treatment with benzodiazepines was allowed. Most of the patients excluded from the study had been treated earlier (75%). All patients were treated with olanzapine at flexible doses between 5 and 20 mg/day. Patients were evaluated at the index episode (baseline) and at 1, 6, and 12 months of treatment using the Positive and Negative Symptom Scale (PANSS) (Peralta and Cuesta, 1994) to evaluate positive, negative, and general symptoms. The clinicianrated Global Assessment of Function Scale (GAF) (American Psychiatric Association, 1994) was used to evaluate a patient's overall level of psychosocial functioning on a scale from 1 to 100, with higher scores indicating better functioning.
In addition, the study included 18 healthy age-matched and sex-matched volunteers (mean age ± S.E.M., 25.19 ± 5.95 years). These healthy controls were also assessed with the PANSS and GAF. All the participants (cases and controls) were recruited from the same community and included after informed consent to participate in the study was obtained. Patients with mental retardation, organic brain disorders or drug abuse as a primary diagnosis were excluded. The exclusion criteria for controls also required the absence of any Axis I disorder. This study was approved by the local ethics committee.
Experimental procedures
The blood samples were taken upon arrival at the hospital emergency room and at 1, 6, and 12 months of treatment (patients only). Blood samples were collected into glass whole-blood tubes containing K3-EDTA. Plasma was isolated by centrifugation at 300 Â g for 10 min, removed and stored frozen at -801C until analyzed. All blood samples from patients and controls were taken between 8 and 11 a.m. to avoid the circadian fluctuations in BDNF levels, which have been reported to occur in men but not in women (Piccinni et al., 2008) . Plasma BDNF levels were measured using a sandwich enzyme-linked immunosorbent assay kit according to the manufacturer's instructions (CYT306 from Chemicon, Chemicon International Inc., Temecula, California, USA). All measurements were performed in duplicate. Absorbencies were determined using a microplate reader (BIO-TEK, Sinergy HT, Bio-Tek Instruments, Inc., Winooski, Vermont, USA) with the wavelength set at 450 nm. Standard curves were constructed using data from duplicate plasma samples. The minimum detection limit was 7.8 pg/ml and the assay range was from 7.8-500 pg/ml. Values are given as mean ± S.E.M. and statistical analysis of the comparisons between the control and patient groups was performed using the nonparametric Mann-Whitney U test. Correlations between BDNF levels and PANSS positive, negative, and general symptom subscores as well as with GAF scores were obtained using the Spearman's test.
Results
Plasma BDNF levels of the 18 patients at onset of psychosis (baseline) were significantly lower than those of the 18 matched healthy control participants (4.09 ± 2.31 vs. 5.80 ± 2.66 ng/ml, Mann-Whitney U = 76; P = 0.05). This indicates that BDNF levels were about 30% lower in the patient group than in the control group at baseline. During olanzapine treatment, plasma BDNF levels of patients increased toward those seen in the control group. There were no significant differences in plasma BDNF levels between the control group (5.80 ± 2.66 ng/ml) and the patient group at 1 month (5.23 ± 2.32 ng/ml, U = 43, P > 0.05), 6 months (5.65 ± 2.53 ng/ml, U = 63, P > 0.05) or 12 months (5.58 ± 2.17 ng/ml, U = 38, P > 0.05).
PANSS positive symptoms were significantly higher in the patient group at baseline compared with the control group: 24.4 ± 4.8 vs. 15.44 ± 7.10, U = 31.5, P < 0.01. Positive symptoms decreased in the patient group during olanzapine treatment. Compared with the control group, PANSS positive symptoms in the patient group were 15.13 ± 7.17 at 1 month (U = 122, P > 0.05), 10.50 ± 3.85 at 6 months (U = 64.5, P = 0.047), and 12.87 ± 5.84 at 12 months (U = 95.5, P > 0.05). PANSS general symptoms were also significantly higher in the patient group at baseline compared with the control group: 40.94 ± 13.95 vs. 31.12 ± 10.24, U = 62.5, P = 0.004. There were no significant differences in general symptoms between the control group and the patient group at 1 month (31.13 ± 10.24, U = 128, P > 0.05), 6 months (27.64 ± 7.9, U = 92.5, P > 0.05), and 12 months (26.00 ± 6.65, U = 87.5, P > 0.05). PANSS negative symptoms were low and similar in the control and patient groups at all time points: control group 13.50 ± 6.90 versus patients at baseline 13.22 ± 6.96 (U = 142, P > 0.05); vs. patients at 1 month 13.50 ± 6.89 (U = 128, P > 0.05); versus patients at 6 months 15.57 ± 9.07 (U = 98, P > 0.05); and versus patients at 12 months 12.80 ± 13.60 (U = 100.5, P > 0.05).
GAF ratings were significantly lower for patients at baseline compared with the control group: 30.22 ± 3.28 versus 50.12 ± 17.65, U = 34, P < 0.01. Patient GAF ratings increased during olanzapine treatment and were comparable to the control group at all three follow-up assessments: 50.13 ± 17.64 at 1 month, U = 128, P > 0.05; 57.43 ± 13.49 at 6 months, U = 82.5, P > 0.05; and 54.80 ± 13.69 at 12 months, U = 97, P > 0.05.
There was a significant positive correlation between plasma BDNF levels and GAF ratings across the study (r: 0.30; P < 0.05) (Fig. 1) . Plasma BDNF levels correlated well and negatively with positive symptoms (r: -0.35; P < 0.05), but correlated poorly with negative symptoms and general psychopathology.
Discussion
The results of this study indicate that olanzapine treatment not only improves psychotic symptoms, but also can restore the reduced plasma BDNF levels seen at the onset of a first psychotic episode to levels comparable with those seen in healthy control participants. These results are consistent with preclinical data showing that olanzapine, like other second-generation antipsychotic drugs, promotes the production of BDNF (Fukumoto et al., 2001; Bai et al., 2003; Angelucci et al., 2004; Luo et al., 2004) , and restores the decrease of BDNF produced after administration of haloperidol (Parikh et al., 2004) or the NMDA antagonist MK-801 (Fumagalli et al., 2003) . Nevertheless, there are some preclinical studies that do not support our findings. Valvassori et al. (2008) found no change in BDNF levels in the hippocampus of male Wistar rats treated chronically with olanzapine. Similarly, Pillai et al. (2006) showed that BDNF levels in rat hippocampus remained unchanged after administering olanzapine for 90 or 180 days. Duration of treatment could explain some of the different data found. Pillai (2008) observed an increase in BDNF expression in the frontal cortex of rats after administration of olanzapine (10 mg/kg/day) for 45 days. In contrast, Brown et al. (2008) observed no changes in BDNF levels in the frontal cortex of rats treated with a lower dose of olanzapine (5 mg/kg/day) for a shorter period of time (28 days). These findings suggest that higher doses of olanzapine and longer treatment periods may favor an increase in BDNF levels. This is consistent with our observation that BDNF levels in plasma increase most notably after several months of olanzapine treatment. However, it is important to note that some preclinical studies did not find increases in BDNF after long-term administration of olanzapine (Pillai et al., 2006; Valvassori et al., 2008) .
Our results are consistent with several clinical studies reporting increases in BDNF levels in the brain and serum of psychotic patients treated with olanzapine. Hammonds and Shim (2009) found that olanzapine treatment for 4 weeks resulted in marginal increases in BDNF levels in the dental gyrus, but not in the hippocampal area CA1. In addition, patients diagnosed with chronic schizophrenia and treated with olanzapine for 6 weeks (n = 10) had a greater increase in serum BDNF levels compared with patients treated with haloperidol, risperidone or amisulpride (Rizos et al., 2008) . Earlier studies have reported that patients diagnosed with schizophrenia (Gama et al., 2007; Buckley et al., 2007b) or bipolar disorder (de Oliveira et al., 2009 ) have reduced serum BDNF levels compared with healthy controls, and that these BDNF levels may increase during antipsychotic treatment. In contrast, however, a study of three different atypical antipsychotics (including 18 Japanese patients treated with olanzapine) found that plasma BDNF levels did not change after 8 weeks of treatment (Yoshimura et al., 2008) . In general, data from studies done in the early stages of psychosis are the most conflicting. One study found increased BDNF levels after treatment of patients with a first psychotic episode (Palomino et al., 2006) , another study found marginal increases in BDNF in the dental gyrus of patients (Hammonds and Shim, 2009) , and a third study found no change in BDNF levels after 8 weeks of treatment (Yoshimura et al., 2008) . This is the first report of the long-term effect of olanzapine treatment on BDNF levels in drug-naive patients with a first psychotic episode. Unlike studies of patients with chronic disorders, data obtained in early psychosis are not confounded by other factors such as chronicity, post-mortem changes, and uncontrolled variables. A longer follow-up allows prospective temporal changes in BDNF levels to be determined.
In our study, we found a correlation between patient functioning (GAF) and plasma BDNF levels, such that patients with higher BDNF levels had better functioning. Plasma BDNF levels also correlated well with positive symptoms (PANSS), such that patients with higher BDNF levels had fewer positive symptoms. There was no correlation between BDNF levels and negative symptoms or general psychopathology. Our observations support earlier findings that olanzapine is effective in the treatment of first psychotic episodes and other psychoses (González-Pinto et al., 2002; Tohen et al., 2003; Green et al., 2006; Tamayo et al., 2007) and improves functional outcome (Kinon et al., 2006) .
Our findings also confirm that a deficit in BDNF may contribute to the structural and functional alterations underlying these psychiatric illnesses, as proposed in earlier studies (Durany and Thome, 2004; Palomino et al., 2006; Buckley et al., 2007b; Pillai, 2008) . In particular, BDNF deficits can impair glutamate signaling and synapse consolidation (Bramham and Messaoudi, 2005) and, thus, may induce excessive synaptic pruning in regions vulnerable to psychosis during late developmental stages associated with disease onset.
The mechanisms by which olanzapine promotes BDNF gene expression are unknown. Among other actions, atypical antipsychotics potentiate glutamate signaling by reducing glutamate uptake in astrocytes in culture and in the prefrontal cortex of patients with schizophrenia . This, in turn, enhances BDNF production by glial cells (Taylor et al., 2003) . However, the complexity of the specific interactions with other neurotransmitter systems suggests that the effects of olanzapine on BDNF levels can be mediated by multiple interactions.
In summary, we provide evidence that peripheral levels of BDNF are reduced at the onset of psychosis and that treatment with olanzapine tends to restore plasma concentrations of this neurotrophic factor.
